VolitionRX (VNRX) investor relations material

Recent achievements

• Cat paper submitted; $5M milestone payment expected if published; Fujifilm Vet Systems launch on automated i10 platform.

• Expansion into non-sepsis disease areas and Mayo Clinic publication in trauma; automated platform installation in Q3 2026.

• Demonstrated utility of rapid, point-of-care finger-prick test in sepsis patients; DETECSEPS on track to launch Q3.

• Certification completed at three French hospitals; manuscripts submitted for peer review and available as preprints.

• Co-marketing agreement in place with Hologic; larger scale programs in confidential discussions.

Executive summary and business model

• Mission to save lives and improve outcomes for people and animals worldwide.

• Focus on licensing IP in cancer and sepsis, with low-cost testing and commercial animal health products.

• $23M in licensing, $1.4M revenue in H1 2026, and 51 patent families as of June 2026.

• Asset-light, platform-agnostic approach; no need for proprietary machines, labs, or sales reps.

• Low capex, low opex business model centered on commercial partnerships and out-licensing.

Technology and product pipeline

• Expertise in quantifying nucleosomes and working at the cutting edge of epigenetics.

• Multiple products launched: Nu.Q Vet, Nu.Q Nets, Nu.Q Cancer, Capture Seq, and Nu.Q Discover.

• Nu.Q Cancer targets $4B TAM, Nu.Q Nets >$3B ICU/ED, Capture Seq $23B, Nu.Q Vet $170M.

• World-first isolation of 99% pure tumor-associated DNA from liquid biopsy; novel biomarkers and proof-of-concept clinical data.

• Rapid, point-of-care finger-prick test for sepsis patients expands use cases and access in low-income countries.